Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-10-03 pm EDT
77.88 USD   +2.50%
10/03Novocure to Report Third Quarter 2022 Financial Results
BU
09/30Insider Sell: Novocure
MT
09/21Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating

07/29/2022 | 11:17am EDT


© MT Newswires 2022
All news about NOVOCURE LIMITED
10/03Novocure to Report Third Quarter 2022 Financial Results
BU
09/30Insider Sell: Novocure
MT
09/21Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Gr..
BU
09/19Insider Sell: Novocure
MT
09/12Insider Sell: Novocure
MT
09/07Insider Sell: Novocure
MT
09/07Transcript : NovoCure Limited Presents at 2022 Wells Fargo Healthcare Confere..
CI
09/06Insider Sell: Novocure
MT
08/31Novocure to Participate in Upcoming Investor Conferences
BU
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
BU
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 547 M - -
Net income 2022 -86,5 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -99,5x
Yield 2022 -
Capitalization 8 157 M 8 157 M -
EV / Sales 2022 15,1x
EV / Sales 2023 14,3x
Nbr of Employees 1 167
Free-Float 98,8%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 77,88 $
Average target price 94,25 $
Spread / Average Target 21,0%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED3.73%8 157
SHOCKWAVE MEDICAL, INC.56.43%10 022
MASIMO CORPORATION-50.63%7 593
PENUMBRA, INC.-34.01%7 410
GETINGE AB-51.48%4 645
ASAHI INTECC CO., LTD.-6.23%4 444